Separately, we can confirm definitively that Merck has boosted its quarterly dividend — to $0.81/share — starting in January 2025, though. [That’s good news for long term holders, to be sure — even with the less than stellar tax effect, of paying cash dividends in US companies.]
But let’s put this one in the category of… not terribly… likely.
There would be little reason for Rahway to need to own the whole cow — when it will always be able to access just the cups of milk it most desires, as a rule.
Yep — it is a repeated rumor — based off of a rumor, thus:
…Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck, the US-listed pharma group, is the latest industry giant to be linked to a takeover bid for Incyte, with which it collaborates on several drug development projects. Merck has a market cap of $244bn, while Incyte is valued at nearly $15bn.
Both refused to comment….”
As we always say — “never say never…” but I am a skeptic here. But do bet on that fat dividend — now approaching 4% a year. Grin — now… go Buffs, beat the Jayhawks!
नमस्ते
Powerline Lies... 